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Background: Chronic obstructive pulmonary disease (COPD) is a chronic, progressive disease 
and is treated with inhaled medication to optimize the patient’s lung health through decreasing 
their symptoms, especially breathlessness. Halotherapy is the inhalation of micronized dry salt 
within a chamber that mimics a salt cave environment. Recent media reports suggest that this 
therapy may help with the symptoms of COPD.
Objective: To critically evaluate and summarize the evidence for the use of halotherapy as a 
treatment for COPD.
Design: A review using systematic approach and narrative synthesis.
Data sources: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE, 
EMBASE, CINAHL, and Google Scholar were searched. Two reviewers independently reviewed 
abstracts and selected eligible studies based on predetermined selection criteria.
Results: Of the 151 articles retrieved from databases and relevant reference lists, only one ran-
domized controlled trial met the inclusion criteria. A meta-analysis was unable to be conducted 
due to the limited number of published studies. Inclusion criteria were subsequently expanded 
to allow three case-control studies to be included, ensuring that a narrative synthesis could be 
completed. From the pooled data of the four studies, there were 1,041 participants (661 in the 
intervention group and 380 in the control group). The assessment of methodological quality 
raised issues associated with randomization and patient selection. Three themes were identified 
from the narrative synthesis: respiratory function, quality of life, and medication use.
Conclusion: Themes generated from the narrative synthesis data reflect outcome measures 
regularly used for interventional research associated with COPD. From this review, recommenda-
tions for inclusion of halotherapy as a therapy for COPD cannot be made at this point and there 
is a need for high quality studies to determine the effectiveness of this therapy.
Keywords: salt therapy, speleotherapy, lung disease, aerosol, chronic disease, salt cave
Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic, progressive disease with 
symptoms of dyspnea, increased respiration rate, sputum production, and a reduced 
exercise intolerance.1 In 2008, the World Health Organization estimated that COPD 
was the tenth most prevalent cause for moderate to severe disability,2 and was the 
fourth leading cause of death, worldwide.3 With this significant burden, the impact 
of this disease on individuals, families’ quality of life, and the associated health care 
expense, COPD is recognized as an international health priority.1,3,4
COPD is managed with inhaled medication with the view to optimize the patient’s 
pulmonary function and reduce symptoms. Pulmonary rehabilitation is recommended 
for those patients with Medical Research Council dyspnea score of 3 or more1 as 





there is substantial evidence of its benefit to these patients.5,6 
 However, other therapies such as speleotherapy and halo-
therapy are being recommended in the wider community7 
and are often described as well-researched treatments for 
people with COPD.8 In Eastern Europe, natural salt caves 
have been used to help relieve symptoms of chest conditions.9 
This therapy is known as speleotherapy, where a natural salt 
cave climate is used as a therapy for ill health.10 The unique 
characteristics of the microclimate within the caves are stable 
air temperature, moderate to high humidity, the presence 
of fine aerosol elements (sodium, potassium, magnesium 
and calcium), as well as a lack of airborne pollutants and 
 pollens.11 Halotherapy builds on this premise and is used as 
an above-ground alternative for speleotherapy.12 Halotherapy 
is a treatment consisting of inhalation of small salt particles 
in a controlled environment of a halochamber.11,12 This room 
is designed to replicate the natural microclimate of a salt 
cave. Halotherapy treatment has been associated with relief 
of respiratory conditions such as asthma, cystic fibrosis, and 
COPD, as well as relieving integumentary conditions such as 
eczema and dermatitis.9,11 A recent study of bronchiectasis 
patients found halotherapy to be of little benefit.13 Despite 
these findings, there appears to be an increasing number of 
commercial halotherapy treatment centers in Australia, the 
United States of America, Europe, and Canada that are aimed 
at treating respiratory and other medical conditions.
Halotherapy has received prominent television media 
coverage in Australia from Channel 9’s A Current Affair8,14,15 
and Channel 7’s Today Tonight7,16 and abroad from Cable 
Network News’ Vital Signs,17 as well as from other television 
program providers such as the British Broadcasting Corpora-
tion18 and the National Broadcasting Corporation.19 National 
and international media current affair and news reports14–16,19 
suggest that halotherapy may help with a variety of respira-
tory illnesses including relieving the symptoms of COPD. The 
assertion behind these reports is that inhaled dry salt therapy 
may assist people with COPD by increasing the liquefaction 
of airway secretions, which, in turn, enhances the expectora-
tion of airway mucous secretions. With the increase in the 
commercial availability of halotherapy as an alternative 
complementary treatment, it is timely to undertake a review 
of this therapy for COPD to appraise the evidence for the 
complementary therapy. An extensive search of a number of 
databases did not identify any published systematic reviews 
that assessed halotherapy as an intervention for people 
with COPD. Therefore, this review sought to  investigate 
Table 1 Summary of included review articles
Article Aim Sample Method NHMRC level  
of evidence
Major findings Strengths and limitations
Nurov (2010)24 To assess the  
immunological features  
of COPD patients after  
speleotherapy
One hundred twenty-four participants randomized into  
two groups. Treatment group 103 participants (60 male,  
43 female) and control group 25 participants (14 male,  
11 female).
Randomized control trial. 
Immunological studies at time 
one (before treatment), at 
time two (after treatment), 
and time three (6 months after 
treatment).
II Increase in concentration subpopulations in all studied  
lymphocytes, normalization and correlation of  
subpopulations of CD4+ and CD8+ lymphocytes, and increase  
in neutrophil phagocytosis activity. Overall immune status  
improvement in 97.8% of treatment group and 67.5% of  
control group.
One treatment facility. Moderate sample size. Randomization 
unblinded. Unequal chance of allocation. Recruitment 
strategy not identified. Nil ethical considerations. Patients’ 
clinical status not reported.
Chervinskaya and  
Ziber (1995)11
To assess the effect of  
halotherapy on various  
types of respiratory  
diseases
Treatment group – 124 participants, 54 males,  
70 females, mean age 34.3±2.5 years. Control group –  
15 participants not described.
Prospective case-control study. 
Lung function studies before and 
after trial.
III-2 After treatment – decreased bronchial obstruction,  
decreased medication use, and increase in FvC, Fev1, PeF.  
Participants slept better, decreased fatigue. Cough became  
less frequent, easier, and more productive.
One treatment facility. Moderate sample size. Recruitment 
strategy not identified. Many respiratory diseases grouped 
together. Nil ethical considerations reported. Control group 
not adequately described before or after treatment.
Oprita et al  
(2010)23
To assess the effects of  
halotherapy on patients  
with asthma and chronic  
obstructive pulmonary  
disease
Two hundred four participants (61% males, mean age  
64 years) received standard treatment and SALTMeD  
treatment. One hundred eighty-nine received only  
standard treatment (64% males, mean age 59 years).
Retrospective case-control 
study. Respiratory characteristics 
reported before treatment and  
1 hour after treatment.
III-2 Respiratory rate, SaO2, PaO2, and PaCO2 were all significantly  
improved in the group receiving the standard treatment in  
combination with the SALTMeD treatment as compared  
to the group receiving only the standard treatment.
One treatment facility. Large sample size. Only short term 
results, no longer term follow up. Asthma and COPD 
results reported together.
Horvath (1986)10 To examine whether  
a stay in a cave  
microclimate could  
further improve  
respiratory symptoms of  
patients with COPD or  
bronchial asthma
One hundred fifty-one participants – (89 males,  
62 females, mean age 46 years, 101 participants with  
chronic bronchitis, 50 with bronchial asthma) treatment  
with climatotherapy. Two hundred thirty participants –  
(137 males, 93 females, mean age 49 years,  
141 participants had chronic bronchitis, 89 had  
bronchial asthma) treatment was CRR consisting of  
speleotherapy in combination with rest, breathing  
exercises and relaxation training.
Retrospective case-control 
study. Clinical state reported 
as improved, unchanged, or 
deteriorated. Medication request 
dosage changes before and after 
3 weeks of treatment. Mean Fev1 
before and after treatment.
III-2 Clinical state improved in group receiving CRR compared  
to 72.8% receiving climatotherapy. For patients receiving  
CRR, Fev1 improved from 1,468±631 mL to 1,676±706 mL  
compared to the patients receiving climatotherapy Fev1  
who improved from 1,638±613 mL to 1,666±684 mL.
One treatment facility. Large sample size. Asthma and 
COPD results reported together. Initial clinical state of 
group receiving CRR was more severe than group receiving 
climatotherapy.
Abbreviations: COPD, chronic obstructive pulmonary disease; CRR, complex respiratory rehabilitation; Fev1, forced expiratory volume in 1 second; FvC, forced vital 
capacity; PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial pressure of oxygen in arterial blood; PEF, peak expiratory flow; SALTMED, saline inhalation; 
SaO2, oxygen saturation.
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 halotherapy as a therapeutic intervention for people with 
COPD to determine the effectiveness of this therapy.
Methods
Search strategy and selection criteria
A search of electronic databases was conducted from January 
2013 to February 2013. The electronic databases searched 
were the Cochrane Central Register of Controlled Trials 
(CENTRAL), PubMed, MEDLINE, EMBASE, CINAHL, 
and Google Scholar. The literature review search strategy 
(Supplementary material) used a combination of MeSH terms 
found in the title and/or abstract for halotherapy and chronic 
obstructive pulmonary disease and the following search 
terms were used: COPD; chronic bronchitis; emphysema; 
halotherapy; halochamber; speleotherapy;  spelaeotherapy; 
cave; salt mine; potash mine; vital air room; climate  chamber; 
saltpipe; and sopipa. Reference lists in retrieved papers were 
hand-searched for other possible studies. All prospective 
randomized controlled trials were included where trials 
compared halotherapy or speleotherapy with a control group. 
Abstract and full text articles that were not in English were 
excluded. After abstracts were retrieved, two reviewers 
applied the inclusion and exclusion criteria. Full text articles 
were subsequently obtained and reviewed by two independent 
reviewers (RR and SMSS) (Table 1). A third reviewer (NJR) 
was the arbiter should any disagreement regarding the inclu-
sion of articles occur.
Quality assessment
The methodological quality of the selected articles was 
assessed by two reviewers (RR and SMSS) using the  Scottish 
Intercollegiate Guidelines Network (SIGN) methodology 
quality checklists for controlled trials and case-control 
 studies (Table 2).20 These checklists were used to assess 
issues pertinent to well-conducted randomized controlled 
trials and case-control studies. The risk of bias was assessed 
using the Cochrane classification with four criteria: sequence 
generation; allocation concealment; blinding; and incomplete 
outcome measurement.21 Any disagreements regarding risk of 
bias were resolved through discussions between the reviewers 
and the arbiter (RR, SMSS, NJR).
Data abstraction
The search revealed 151 published abstracts after excluding 
the duplicates. The abstracts were screened using the selec-
tion criteria and 150 articles were excluded. The flow diagram 
of the selection process is illustrated in Figure 1. Only one 
randomized study met the inclusion criteria; therefore, it 
Table 1 Summary of included review articles
Article Aim Sample Method NHMRC level  
of evidence
Major findings Strengths and limitations
Nurov (2010)24 To assess the  
immunological features  
of COPD patients after  
speleotherapy
One hundred twenty-four participants randomized into  
two groups. Treatment group 103 participants (60 male,  
43 female) and control group 25 participants (14 male,  
11 female).
Randomized control trial. 
Immunological studies at time 
one (before treatment), at 
time two (after treatment), 
and time three (6 months after 
treatment).
II Increase in concentration subpopulations in all studied  
lymphocytes, normalization and correlation of  
subpopulations of CD4+ and CD8+ lymphocytes, and increase  
in neutrophil phagocytosis activity. Overall immune status  
improvement in 97.8% of treatment group and 67.5% of  
control group.
One treatment facility. Moderate sample size. Randomization 
unblinded. Unequal chance of allocation. Recruitment 
strategy not identified. Nil ethical considerations. Patients’ 
clinical status not reported.
Chervinskaya and  
Ziber (1995)11
To assess the effect of  
halotherapy on various  
types of respiratory  
diseases
Treatment group – 124 participants, 54 males,  
70 females, mean age 34.3±2.5 years. Control group –  
15 participants not described.
Prospective case-control study. 
Lung function studies before and 
after trial.
III-2 After treatment – decreased bronchial obstruction,  
decreased medication use, and increase in FvC, Fev1, PeF.  
Participants slept better, decreased fatigue. Cough became  
less frequent, easier, and more productive.
One treatment facility. Moderate sample size. Recruitment 
strategy not identified. Many respiratory diseases grouped 
together. Nil ethical considerations reported. Control group 
not adequately described before or after treatment.
Oprita et al  
(2010)23
To assess the effects of  
halotherapy on patients  
with asthma and chronic  
obstructive pulmonary  
disease
Two hundred four participants (61% males, mean age  
64 years) received standard treatment and SALTMeD  
treatment. One hundred eighty-nine received only  
standard treatment (64% males, mean age 59 years).
Retrospective case-control 
study. Respiratory characteristics 
reported before treatment and  
1 hour after treatment.
III-2 Respiratory rate, SaO2, PaO2, and PaCO2 were all significantly  
improved in the group receiving the standard treatment in  
combination with the SALTMeD treatment as compared  
to the group receiving only the standard treatment.
One treatment facility. Large sample size. Only short term 
results, no longer term follow up. Asthma and COPD 
results reported together.
Horvath (1986)10 To examine whether  
a stay in a cave  
microclimate could  
further improve  
respiratory symptoms of  
patients with COPD or  
bronchial asthma
One hundred fifty-one participants – (89 males,  
62 females, mean age 46 years, 101 participants with  
chronic bronchitis, 50 with bronchial asthma) treatment  
with climatotherapy. Two hundred thirty participants –  
(137 males, 93 females, mean age 49 years,  
141 participants had chronic bronchitis, 89 had  
bronchial asthma) treatment was CRR consisting of  
speleotherapy in combination with rest, breathing  
exercises and relaxation training.
Retrospective case-control 
study. Clinical state reported 
as improved, unchanged, or 
deteriorated. Medication request 
dosage changes before and after 
3 weeks of treatment. Mean Fev1 
before and after treatment.
III-2 Clinical state improved in group receiving CRR compared  
to 72.8% receiving climatotherapy. For patients receiving  
CRR, Fev1 improved from 1,468±631 mL to 1,676±706 mL  
compared to the patients receiving climatotherapy Fev1  
who improved from 1,638±613 mL to 1,666±684 mL.
One treatment facility. Large sample size. Asthma and 
COPD results reported together. Initial clinical state of 
group receiving CRR was more severe than group receiving 
climatotherapy.
Abbreviations: COPD, chronic obstructive pulmonary disease; CRR, complex respiratory rehabilitation; Fev1, forced expiratory volume in 1 second; FvC, forced vital 
capacity; PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial pressure of oxygen in arterial blood; PEF, peak expiratory flow; SALTMED, saline inhalation; 
SaO2, oxygen saturation.





Table 2 Methodological assessment of included articles
 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11  
Randomized  
controlled trial
Aims Randomization Concealment Double blinding Similar TG and CG Treatment is the only 
difference between  
TG and CG
Outcome measured  
in standard, valid,  
reliable way
Drop out  
percentage
Intention to treat  
analysis
Results comparable  
for all sites
– Overall acceptability 
(++, +, -)
Nurov (2010)24   Unable to report     Not reported  N/A +
Case-control  
studies




Percentage of cases  
and controls
Comparison of cases  
and controls
Clearly defined cases Clearly defined  
controls
Concealment Outcome measured in  
standard, valid, reliable way
Address possibility of  
confounding factors




Chervinskaya and  
Ziber (1995)11
 Unable to  
report
Unable to report Unable to report    Unable to report    –
Oprita et al  
(2010)23
   Unable to report    Retrospective  
case-control study
   ++
Horvath (1986)10   Unable to report Unable to report    Retrospective  
case-control study
   +
Note: Overall acceptability is indicated by (-) unacceptable, (+) acceptable, and (++) excellent. 
Abbreviations: Q, question number; CG, control group; TG, treatment group.
was not possible to undertake the meta-analysis. The inclu-
sion criteria were expanded and a further three case-control 
trials were included. A number of commentary papers 
were excluded. The two reviewers (RR and SMSS) were 
in agreement for the studies to be included and the arbiter 
(NJR) was not required to resolve any conflicting opinion. On 
completion of the methodological quality assessment, each 
manuscript was summarized and, due to the heterogeneity 
of reported outcomes, a thematic analysis was conducted. 
Thematic analysis is a process that seeks to describe the data 
in rich detail in order to identify, analyze, and report patterns 
known as themes from within the data.22 The combined data 
of the four studies were analyzed thematically.
Findings
Thematic analysis
Summary data including characteristics of the study regard-
ing the four studies are summarized in Table 1. The three 
themes identified from the data were respiratory function, 
quality of life, and medication use.
Respiratory function
All of the case-control studies (n=3) reported improved respi-
ratory function to varying degrees and detailed improvements 
in many lung function tests including forced vital capacity, 
forced expiratory volume in 1 second (FEV
1
), oxygen satura-
tion, partial pressure of oxygen in arterial blood, and partial 
pressure of carbon dioxide in arterial blood. Although the 
lung function tests utilized by the researchers are a reliable 
method to assess respiratory function, each study reported 
using different tests which made any comparison of the 
results difficult.
Oprita et al23 report that, after 60 minutes of treatment, 
there was an improvement in oxygen saturation from 90% 
to 98% in the treatment group (n=204) as compared to 
the control group (n=189) improving from 94% to 97%. 
 Similarly, the improvement in partial pressure of oxygen in 
arterial blood for the treatment group was from 61.5 mmHg 
to 92 mmHg compared to 80 mmHg to 85 mmHg for the 
control group. The partial pressure of carbon dioxide in 
arterial blood considerably decreased in the treatment group 
from 58 mmHg to 38 mmHg and in the control group from 
44 mmHg to 41 mmHg.
Horvath10 documented an improved respiratory func-
tion by measuring the FEV
1
 before and after treatment. The 
mean FEV
1
 for the treatment group (n=230) improved from 
1.47±0.631 L to 1.68±0.71 L after patients were enrolled 
in a complex respiratory rehabilitation that included spe-
leotherapy for a specific time period. The control group 
(n=151), who received climatotherapy, had an improvement 
from 1.64±0.61 L to 1.67±0.68 L. Nurov’s24 study reported 
improved immune function after speleotherapy but did not 
report specifically on lung function of COPD patients. Nurov 
concluded that patients with COPD receiving speleotherapy 
improved their immunological status and, as a consequence, 
reduced the inflammatory process particularly during 
exacerbations.
Quality of life
Horvath10 and Chervinskaya and Ziber11 reported speleother-
apy and halotherapy (respectively) as improving the quality 
of life for patients suffering from COPD. Horvath reported 
that 90.4% of patients receiving the speleotherapy improved 
their clinical state in comparison to 72.8% of patients in the 
control group. The participants’ clinical state was scored each 
day by the participant and physician jointly on the basis of 
symptoms and complaints. The authors suggested that the 
improved clinical state for COPD patients improves their life 
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quality by decreasing exacerbations, reducing hospitalization, 
improving physical tolerance, and reducing fatigue. Nurov24 
reported that positive shifts in immunological status resulted 
in improved clinical symptoms, but elaboration or description 
of clinical symptoms were not provided.
Medication use
The use of medication was an outcome measured in two halo-
therapy studies. Chervinskaya and Ziber11 and  Horvath10 indi-
cated that patients were able to decrease their  medications. 
Chervinskaya and Ziber reported that up to 50% of patients 
in their study were able to discontinue their inhaled cortico-
steroids therapy and nearly a third of participants continued 
their inhaled steroid therapy at reduced dosages. In Horvath’s 
study, medication use was recorded as a bi-level outcome with 
the first outcome being reduction or omission and the second 
outcome being an unchanged dosage. However, with 95% of 
participants having either reduced or omitted medication, the 
type of medication or dosage is not detailed. 
Discussion
From this review of literature, it has become apparent that 
there have been very few rigorous studies published on this 
topic and, hence, this reduces the potential for evidence to 
support this therapy. It should be noted that only one random-
ized trial was found after an extensive search of the literature. 
As a result, the inclusion criteria for this review were widened 
to include relevant case-control studies that met all other 
inclusion criteria. The randomized trial by Nurov24 studied 
the immunological features of patients with COPD before 
and after speleotherapy, demonstrating increased levels of 
lymphocytes and increased neutrophil phagocytosis activity. 
When assessing the methodological quality of studies 
included in this review, a number of concerns were identified. 
Specifically, in Nurov’s study, the method of randomization 
appeared unclear and there was a lack of detail regarding 
demographic and disease related information including 
medications being used by participants.
Other concerns related to the studies included in 
this review pertain to the lack of detail in regard to the 
 participants’ primary medical condition of either asthma 
or COPD and discrimination in the results between these 
two medical conditions. Medication information including 
type and dosage was also lacking in all studies. There were 
significant differences at baseline between treatment and 
control arms in the study by Oprita et al23 and the treatment 
group appeared to have more severe COPD. In Horvath’s5 
study, the patients in the treatment group had a significantly 
lower FEV
1
 prior to the intervention than the control group. 
Whilst the Oprita study appears to be a well-constructed 
retrospective case-control study with positive results for the 
use of sodium chloride dry aerosols, as the investigators only 
assessed patients 1 hour after treatment, longer term conclu-
sions such as quality of life would be difficult to assess.
In light of the lack of scientific evidence for the use of 
halotherapy in COPD, future studies need to be designed to 
provide the best available evidence and randomized con-
trolled trials need to be considered. This approach would 
address the methodological concerns identified through this 
review such as participant selection bias, blinding of partici-
pants to the intervention, and the concealment of allocation 
to intervention or control group.
Study limitations
The limitations associated with this review were restricted 
by the availability of published research associated with 
halotherapy as a therapeutic intervention for COPD. 
The studies included in this review were found to have a 















151 abstracts screened 131 records excluded
20 full text articles
retrieved
19 records excluded 
with reasons
1 RCT on halotherapy and
COPD
3 case-control studies
relevant to halotherapy and
COPD
4 studies to be included in
a narrative synthesis
Reviewed inclusion/exclusion
criteria changed to include
case-control studies
Figure 1 Flow chart of systematic search.
Abbreviations: COPD, chronic obstructive pulmonary disease; RCT, randomized controlled trial.
number of methodological concerns and limited reporting 
of baseline data. All studies in this review lacked detail on 
ethical considerations such as ethical approval, processes 
for informed patient consent, and funding disclosure. The 
outcome measurements using lung function tests varied 
between studies and, as such, a comparison of their results 
was not possible.
Conclusion
For halotherapy to be considered as an evidence based therapy 
for people with COPD, there needs to be high  quality research 
undertaken to fully examine the effects of this therapy and its 
impact on the quality of life of people with COPD.
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Supplementary material  
Search strategy
A systematic search of the bibliographic databases was 
conducted using the following search terms: COPD or 
“Chronic bronchitis” or Emphysema and Halotherapy* or 
 halochamber* or spelaeo* or speleo* or cave* or salin* 
or “salt min*” or “potash min*” or subterraneotherap* or 
“vital air room” or “climat* chamber” or karst* or SaltPipe 
or Sopipa.
